Journal
EPIGENOMICS
Volume 7, Issue 1, Pages 103-118Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/EPI.14.69
Keywords
autoimmune response; cancer; epigenetics; HDAC6; HDAC6 inhibitor; histone deacetylase; neurodegenerative disease
Categories
Funding
- Televie Luxembourg fellowship
- Action Lions 'Vaincre le Cancer'
- Televie Luxembourg
- 'Recherche Cancer et Sang' foundation
- 'Recherches Scientifiques Luxembourg' association
- 'Een Haerz fir Kriibskrank Kanner' association
- NRF by the MEST of Korea [GCRC 2012-0001184]
- Seoul National University (SNU)
- Research Settlement Fund for the new faculty of SNU
- Research Institute of Pharmaceutical Sciences
Ask authors/readers for more resources
Histone deacetylase (HDAC) 6 is a member of the class IIb HDAC family. This enzyme is zinc-dependent and mainly localized in the cytoplasm. HDAC6 is a unique isoenzyme with two functional catalytic domains and specific physiological roles. Indeed, HDAC6 deacetylates various substrates including alpha-tubulin and HSP90 alpha, and is involved in protein trafficking and degradation, cell shape and migration. Consequently, deregulation of HDAC6 activity was associated to a variety of diseases including cancer, neurodegenerative diseases and pathological autoimmune response. Therefore, HDAC6 represents an interesting potential therapeutic target. In this review, we discuss structural features of this histone deacetylase, regulation of its expression and activity, biological functions, implication in human disease initiation and progression. Finally will describe novel and selective HDAC6 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available